PH12013502568B1 - Anti-psgl-1 antibodies and uses thereof - Google Patents

Anti-psgl-1 antibodies and uses thereof

Info

Publication number
PH12013502568B1
PH12013502568B1 PH1/2013/502568A PH12013502568A PH12013502568B1 PH 12013502568 B1 PH12013502568 B1 PH 12013502568B1 PH 12013502568 A PH12013502568 A PH 12013502568A PH 12013502568 B1 PH12013502568 B1 PH 12013502568B1
Authority
PH
Philippines
Prior art keywords
antibodies
psgl
cells
polynucleotides
kits
Prior art date
Application number
PH1/2013/502568A
Other languages
English (en)
Other versions
PH12013502568A1 (en
Inventor
Stefan Bassarab
Barbara Enenkel
Patrick Garidel
Tobias Litzenburger
Heidrun Schott
Sanjaya Singh
Original Assignee
Abgenomics Coop U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013502568(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Coop U A filed Critical Abgenomics Coop U A
Publication of PH12013502568A1 publication Critical patent/PH12013502568A1/en
Publication of PH12013502568B1 publication Critical patent/PH12013502568B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2013/502568A 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof PH12013502568B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13
PCT/US2012/042068 WO2012174001A1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
PH12013502568A1 PH12013502568A1 (en) 2014-01-27
PH12013502568B1 true PH12013502568B1 (en) 2018-08-10

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/502568A PH12013502568B1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Country Status (21)

Country Link
US (4) US20130209449A9 (enExample)
EP (2) EP2718325A4 (enExample)
JP (1) JP6180408B2 (enExample)
KR (1) KR102103036B1 (enExample)
CN (3) CN108892726A (enExample)
AU (1) AU2012271845B2 (enExample)
BR (1) BR112013031892A2 (enExample)
CA (1) CA2838952C (enExample)
CL (1) CL2013003570A1 (enExample)
CO (1) CO6940376A2 (enExample)
EC (1) ECSP14013132A (enExample)
IL (2) IL229844B (enExample)
MX (1) MX358447B (enExample)
NZ (1) NZ619524A (enExample)
PH (1) PH12013502568B1 (enExample)
RU (1) RU2650817C2 (enExample)
SG (1) SG10201604767TA (enExample)
TW (1) TWI643872B (enExample)
UA (1) UA114712C2 (enExample)
WO (1) WO2012174001A1 (enExample)
ZA (1) ZA201400209B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
AR048840A1 (es) 2004-05-11 2006-05-31 Boehringer Ingelheim Int Epitopes inductores de la muerte de las celulas t
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
CA2953706A1 (en) * 2014-07-08 2016-01-14 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
AU2017206074B2 (en) * 2016-01-08 2023-09-07 Altrubio Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
KR20240151866A (ko) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
EP3820902A2 (en) 2018-07-11 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
KR20220042055A (ko) * 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
EP4139002A2 (en) * 2020-05-22 2023-03-01 Formycon AG Ace2-fc fusion proteins and uses thereof
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
KR20240107151A (ko) * 2021-11-17 2024-07-08 알트루바이오 인코퍼레이티드 T-세포 매개 염증 질환 또는 암을 치료하기 위해 jak 억제제와 조합하여 항-psgl-1 항체를 사용하는 방법
WO2024057232A1 (en) * 2022-09-13 2024-03-21 Tetherex Pharmaceuticals Corporation Antibodies, compositions, and methods of treatment
WO2025106784A1 (en) * 2023-11-17 2025-05-22 Altrubio Inc. Anti-psgl-1 antibodies and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
EP0640131B1 (en) 1992-03-17 1999-04-21 Novartis AG Genetically engineered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
JPH08506017A (ja) 1993-01-25 1996-07-02 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ドメインの交換によるキメラｌ‐およびｐ‐セレクチン、ならびにそれらの使用
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
CA2228512A1 (en) 1995-08-03 1997-02-20 The Board Of Regents Of The University Of Oklahoma Peptide and o-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
JP2002528513A (ja) 1998-10-30 2002-09-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｐ−セレクチンリガンド（ｐｓｇｌ）アンタゴニストによる細胞毒性ｔ−細胞分化の阻害
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
CA2408883A1 (en) 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP1325123A4 (en) 2000-09-12 2004-07-21 Inst Genetics Llc INHIBITION OF STENOSIS OR RESTENOSIS USING P-SELECTINE ANTAGONISTS
KR20030091953A (ko) 2000-12-29 2003-12-03 사비언트 파마슈티컬즈 인코퍼레이티드 황산화된 부분을 함유하는 에피토프를 포함하는 분리된분자, 그러한 에피토프에 대한 항체, 및 그들의 용도
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
JP2005536199A (ja) 2002-07-01 2005-12-02 サビエント ファーマシューティカルズ，インコーポレイティド 抗体及びそれらの使用
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
KR20060107501A (ko) 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
TW200540186A (en) * 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
WO2005080586A1 (en) * 2004-02-13 2005-09-01 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic rnases
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
AR048840A1 (es) 2004-05-11 2006-05-31 Boehringer Ingelheim Int Epitopes inductores de la muerte de las celulas t
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
RS53402B (sr) * 2007-03-22 2014-10-31 Genentech, Inc. Vezivanje apoptotskih anti-ige antitela za membranski ige
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CA2688275A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
EA200901646A1 (ru) 2007-06-05 2010-08-30 Йел Юниверсити Ингибиторы рецепторных тирозинкиназ и их применение
EP2190480A4 (en) 2007-08-28 2013-01-23 Biogen Idec Inc ANTI-IGR-1R ANTIBODIES AND ITS USES
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
EP3388527A1 (en) * 2008-05-15 2018-10-17 Tetherex Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
EP3157560A4 (en) 2014-06-20 2018-02-21 Abgenomics International Inc. Her2 antibody-drug conjugates

Also Published As

Publication number Publication date
TWI643872B (zh) 2018-12-11
US20130251708A1 (en) 2013-09-26
US20130011391A1 (en) 2013-01-10
IL287270A (en) 2021-12-01
UA114712C2 (uk) 2017-07-25
WO2012174001A1 (en) 2012-12-20
US20240124604A1 (en) 2024-04-18
SG10201604767TA (en) 2016-08-30
TW201302791A (zh) 2013-01-16
JP6180408B2 (ja) 2017-08-16
RU2650817C2 (ru) 2018-04-17
KR20140066153A (ko) 2014-05-30
MX2013014814A (es) 2014-07-22
ECSP14013132A (es) 2015-04-30
RU2013158083A (ru) 2015-09-20
AU2012271845B2 (en) 2017-07-27
CO6940376A2 (es) 2014-05-09
JP2014519524A (ja) 2014-08-14
EP3925978A1 (en) 2021-12-22
US20210395383A1 (en) 2021-12-23
US20130209449A9 (en) 2013-08-15
ZA201400209B (en) 2020-05-27
CL2013003570A1 (es) 2014-08-22
CN103732626A (zh) 2014-04-16
IL229844B (en) 2022-02-01
CN108892726A (zh) 2018-11-27
US11897964B2 (en) 2024-02-13
CA2838952A1 (en) 2012-12-20
CA2838952C (en) 2020-11-24
BR112013031892A2 (pt) 2016-11-22
KR102103036B1 (ko) 2020-04-22
EP2718325A4 (en) 2015-03-11
AU2012271845A1 (en) 2014-01-23
EP2718325A1 (en) 2014-04-16
NZ619524A (en) 2016-10-28
MX358447B (es) 2018-08-21
PH12013502568A1 (en) 2014-01-27
CN116063522A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
PH12013502568B1 (en) Anti-psgl-1 antibodies and uses thereof
MY171038A (en) Bispecific antigen binding molecules
MY169358A (en) Bispecific t cell activating antigen binding molecules
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
MY184889A (en) T cell activating bispecific antigen binding molecules
MY179611A (en) Bispecific t cell activating antigen binding molecules
MX374906B (es) Nuevos inmunoconjugados
PH12014501108A1 (en) Anti-il-36r antibodies
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
MX359854B (es) Anticuerpos anti-cxcr3.
UA116766C2 (uk) Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
PH12015500113A1 (en) Anti-kit antibodies and uses thereof
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX358991B (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
TH157671A (th) แอนติ-psgl-1 แอนติบอดีและการใช้ของมัน
TN2013000265A1 (en) Anti-cd38 antibodies